https://doi.org/10.4081/aiua.2024.12756

Evaluation of the effect of daily tadalafil 5 mg vs. daily sildenafil 25 mg on neutrophil-lymphocyte and platelet-lymphocyte ratios in patients with erectile dysfunction: A comparative randomized controlled study

Vol. 96 No. 4 (2024)
Submitted: June 27, 2024
Accepted: July 11, 2024
Published: October 29, 2024
Erectile dysfunction, neutrophils/lymphocytes (NLR), platelets/lymphocytes (PLR), tadalafil, sildenafil
Abstract Views: 550
PDF: 156
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Abdel Rahman Bakry
Department of Andrology & STDs, Faculty of Medicine, Assiut University, Egypt.
Ali Mohamed Mahran
Department of Andrology & STDs, Faculty of Medicine, Assiut University, Egypt.
Hisham Diab Gaber
Department of Andrology & STDs, Faculty of Medicine, Assiut University, Egypt.
Mohamed Ismail Sedek
Department of Clinical Pathology, Faculty of Medicine, Assiut University, Egypt.
Sameh Fayek GamalEl Din
samehfayek@kasralainy.edu.eg
https://orcid.org/0000-0003-1918-5132
Department of Andrology & STDs, Kasr Alainy Faculty of Medicine, Cairo University, Giza, Egypt.
Ahmad Tarek Motawi
Department of Andrology & STDs, Kasr Alainy Faculty of Medicine, Cairo University, Giza, Egypt.
Mohamed Diab Mohamed
Department of Andrology & STDs, Faculty of Medicine, Assiut University, Egypt.
Ahmed Elshebany
Department of Andrology & STDs, Faculty of Medicine, Assiut University, Egypt.

Background: Previous studies had shown that the neutrophils/lymphocytes (NLR) and platelets/lymphocytes (PLR) ratios could be used as markers of inflammatory load as well as prognostic factors in several medical conditions. The current study aimed to compare the effect of using daily tadalafil 5 mg/day versus daily sildenafil 25 mg/day in improving erectile function as well as their ability to reduce NLR and PLR.

Methods: One hundred and four participants were recruited. Seventy-four randomized patients with erectile dysfunction were equally divided into 2 groups. Patients in group A used daily tadalafil 5 mg for 2 months while patients in group B used daily sildenafil 25 mg for 2 months. Patients were collected from June 2022 to June 2023. Thirty healthy individuals served as controls. All patients and controls were evaluated using the validated Arabic version of the international index of erectile function (ArIIEF-5) at baseline and after 2 months of medical treatment. Five cc of venous blood sample was obtained before and after 2 months of medical treatment to compare the effect of phosphodiesterase type 5 inhibitors (PDE-5Is) intake for erectile dysfunction on PLR and NLR before and after treatment.

Results: The current study showed that there were no statistically significant differences between the cases and the controls apart from the ArIIEF-5 scores. Moreover, there was no significant difference between patients in group A and those in group B regarding PLR and NLR post administration of PDE-5Is. Interestingly, patients in group A demonstrated a highly significant difference between the ArIIEF-5 scores as well as the PLR and the NLR before and 2 months after administration of daily tadalafil 5 mg. On the other hand, patients in group B who were administrated daily sildenafil 25 mg for 2 months demonstrated only a highly significant difference between the ArIIEF-5 scores before and after administration. Meanwhile, patients in group B did not reveal any statistically significant difference in the PLR and the NLR before and 2 months after administration of sildenafil 25 mg. Further regression analysis after adjustment of different variables of the study showed a significant correlation between ArIIEF-5 and PLR in patients who received daily tadalafil 5 mg (r=0.430, p=0.004).

Conclusions: Tadalafil and sildenafil have similar clinical efficacy in treating erectile dysfunction. However, tadalafil is more effective in lowering PLR and NLR compared to sildenafil.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Citations

Crossref
Scopus
Google Scholar
Europe PMC
Impotence NIH Consensus Development Panel on Impotence. JAMA1993; 70:83–90.
Burnett AL. Evaluation and management of erectile dysfunction. In L. R. Kavoussi, A. C. Novick, A. W. Partin, & C. A. Peters Içinde (eds.), Campell‐Walsh Urology. Philadelphia, PA: Elsevier. 2012; pp. 721–48.
Bhat T, Teli S, Rijal J, et al. Neutrophil to lymphocyte ratio and cardiovascular diseases: a review. Expert review of cardiovascular therapy. Expert Rev Cardiovasc Ther 2013;11:55-9.
Feng JR, Qiu X, Wang F, et al. Diagnostic value of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in Crohn's disease. Gastroenterol Res Pract 2017;2017:3526460.
Zhang Y, Feng X, Wu X, et al. A systematic review and meta-analysis of the relationship between erectile dysfunction and the neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios. Andrologia 2022;54:e14337.
Liao Z, Tang Y, Li X, Li D. The relationship between hematologic parameters and erectile dysfunction. Sex Med 2021; 9:100401.
Winterbourn CC, Kettle AJ, Hampton MB. Reactive Oxygen Species and Neutrophil Function. Annu Rev Biochem. 2016;85:765-92.
Thomas MR, Storey RF. The role of platelets in inflammation. Thromb Haemost 2015;114:449-58.
Karabakan M, Bozkurt A. Relationship Between Erectile Dysfunction, the Neutrophil-to-Lymphocyte Ratio, and the Platelet-to-Lymphocyte Ratio. J Acad Res Med. 2019; 9:27-31.
Furuncuoǧlu Y, Tulgar S, Dogan AN, et al. How obesity affects the neutrophil/lymphocyte and platelet/lymphocyte ratio, systemic immune-inflammatory index and platelet indices: a retrospective study. Eur Rev Med Pharmacol Sci 2016;20:1300-6.
Diniz LR, de Lima SG, de Amorim Garcia JM,de Oliveira Diniz KL. Neutrophil to Lymphocyte Ratio as a Prognostic Predictor in Older People With Acute Coronary Syndrome. Angiology 2019;70:264-71.
Santi D, Giannetta E, Isidori AM, et al. Therapy of endocrine disease: effects of chronic use of phosphodiesterase inhibitors on endothelial markers in type 2 diabetes mellitus: a meta-analysis. Eur J Endocrinol 2015; 172:R103-14.
Das UN. Is erectile dysfunction a low-grade systemic inflammatory condition? Eur Heart J 2007;28:642-3.
World Medical Association. World Medical Association Declaration of Helsinki: Ethical principles for medical research involving human subjects. JAMA 2013; 310: 2191–2194.
Shamloul R, Ghanem H, Abou-Zeid A. Validity of the Arabic version of the sexual health inventory for men among Egyptians. Int J Impot Res 2004; 16:452-5.
Demirci A, Ozgur BC. The effect of using tadalafil 5 mg/day on neutrophil–lymphocyte and platelet–lymphocyte ratios in mild-medium and severe erectile dysfunction patients; and comparison of clinical response. Andrologia 2019; 51:e13347.
Aslan A, Kaya Y, Cirakoglu A, et al. Neutrophil-Lymphocyte Ratio Could Be a Marker for Erectile Dysfunction. Urol J 2019;16:216-20.
Zhang Y, Feng X, Wu X, et al. A systematic review and meta-analysis of the relationship between erectile dysfunction and the neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios. Andrologia. 2022;54:e14337.
Ventimiglia E, Cazzaniga W, Pederzoli F, et al. The role of neutrophil-to-lymphocyte ratio in men with erectile dysfunction—preliminary findings of a real-life cross-sectional study. Andrology 2018; 6:559-63.
Akbas A, Gulpınar MT, Sancak EB, et al. The relationship between platelet–lymphocyte ratio and severity of erectile dysfunction. Kaohsiung J Med Sci 2016; 32:91-5.
Kilic M, Erkan A, Zengin S, et al. Inflammatory biomarkers may predict response to phosphodiesterase type 5 inhibitor treatment in patients with erectile dysfunction. Investig Clin Urol 2023;64:404-411.
Gong B, Ma M, Xie W, et al. Direct comparison of tadalafil with sildenafil for the treatment of erectile dysfunction: a systematic review and meta-analysis. Int Urol Nephrol. 2017;49:1731-40.
Rubio-Aurioles E, Porst H, Kim ED, et al. A randomized open-label trial with a crossover comparison of sexual self-confidence and other treatment outcomes following tadalafil once a day vs. tadalafil or sildenafil on-demand in men with erectile dysfunction. J Sex Med 2012;9:1418-29.
La Vignera S, Condorelli RA, et al. Functional characterization of platelets in patients with arterial erectile dysfunction. Andrology. 2014; 2:709-15.
GamalEl Din SF, Nabil Ismail N, Moawad HH, et al. Evaluation of tadalafil supplementation on the neutrophil/lymphocyte and the platelet/lymphocyte ratios in patients with erectile dysfunction: A prospective study. Urologia 2024;91:598-603.
Mirone V, Fusco F, Rossi A, et al. Tadalafil and vardenafil vs sildenafil: a review of patient-preference studies. BJU Int. 2009;103:1212-7. Erratum in: BJU Int. 2011;107:1166.
Von Keitz A, Rajfer J, Segal S, et al. A multicenter, randomized, double-blind, crossover study to evaluate patient preference between tadalafil and sildenafil. Eur Urol 2004; 45: 499–509.
Eardley I, Montorsi F, Jackson G, et al. Factors associated with preference for sildenafil citrate and tadalafil for treating erectile dysfunction in men naive to phosphodiesterase 5 inhibitor therapy: post hoc analysis of data from a multicentre, randomized, open-label, crossover study. BJU Int 2007;100:122– 9.
Eardley I, Mirone V, Montorsi F, et al. An open-label, multicentre, randomized, crossover study comparing sildenafil citrate and tadalafil for treating erectile dysfunction in men naïve to phosphodiesterase 5 inhibitor therapy. Sex Med 2005; 96:1323–32.
Rodriguez Tolra JR, Cuadrado Campaña JM, Fumadó Ciutat L, Franco Miranda E. Prospective, randomized, open-label, fixed dose, crossover study to establish preference of patients with erectile dysfunction after taking the three PDE-5 inhibitors. J Sex Med 2006; 3:901-9.

How to Cite

Bakry, A. R., Mahran, A. M., Gaber, H. D., Sedek, M. I., GamalEl Din, S. F., Motawi, A. T., Mohamed, M. D., & Elshebany, A. (2024). Evaluation of the effect of daily tadalafil 5 mg <i>vs.</i> daily sildenafil 25 mg on neutrophil-lymphocyte and platelet-lymphocyte ratios in patients with erectile dysfunction: A comparative randomized controlled study. Archivio Italiano Di Urologia E Andrologia, 96(4). https://doi.org/10.4081/aiua.2024.12756
Copyright (c) 2024 the Author(s) Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.